|
|
||||||||
CLINICAL STUDIES |
1 Endocrinology, Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Novara, Via Solaroli, 17, 28100 Novara, Italy2 Division of Pediatrics,, Amedeo Avogadro University of Novara, 28100 Novara, Italy3 Department of Endocrinology,, Federico II University of Naples, 80100 Naples, Italy4 Division of Endocrinology and Metabolic Diseases,, University of Turin, 10100 Turin, Italy5 Endocrinology Service,, Regina Elena Cancer Institute, 00100 Rome, Italy6 Division of Pediatric Endocrinology,, Hospital of Treviglio, 24047 Treviglio, Italy7 Department of Pediatrics,, IRCCS G. Gaslini, University of Genoa, 16100 Genoa, Italy8 Division of Pediatrics,, University of Parma, 8100 Parma, Italy9 Eli-Lilly,, Florence, Italy and 10 Division of Pediatrics,, Federico II University of Naples, Naples, Italy
(Correspondence should be addressed to G Aimaretti; Email: gianluca.aimaretti{at}med.unipmn.it)
Objective: To define the appropriate diagnostic cut-off limits for the GH response to GHRH+arginine (ARG) test and IGF-I levels, using receiver operating characteristics (ROC) curve analysis, in late adolescents and young adults.
Design and methods: We studied 152 patients with childhood-onset organic hypothalamic–pituitary disease (85 males, age (mean±S.E.M.): 19.2±0.2 years) and 201 normal adolescents as controls (96 males, age: 20.7±0.2 years). Patients were divided into three subgroups on the basis of the number of the other pituitary hormone deficits, excluding GH deficiency (GHD): subgroup A consisted of 35 panhypopituitary patients (17 males, age: 21.2±0.4 years), subgroup B consisted of 18 patients with only one or with no more than two pituitary hormone deficits (7 males, age: 20.2±0.9 years); and subgroup C consisted of 99 patients without any known hormonal pituitary deficits (60 males, age: 18.2±0.2 years). Both patients and controls were lean (body mass index, BMI<25 kg/m2). Patients in subgroup A were assumed to be GHD, whereas in patients belonging to subgroups B and C the presence of GHD had to be verified.
Results: For the GHRH+ARG test, the best pair of highest sensitivity (Se; 100%) and specificity (Sp; 97%) was found choosing a peak GH of 19.0 µg/l. For IGF-I levels, the best pair of highest Se (96.6%) and Sp (74.6%) was found using a cut-off point of 160 µg/l (SDS: –1.3). Assuming 19.0 µg/l to be the cut-off point established for GHRH+ARG test, 72.2% of patients in subgroup B and 39.4% in subgroup C were defined as GHD. In patients belonging to group B and C and with a peak GH response <19 µg/l to the test, IGF-I levels were lower than 160 µg/l (or less than 1.3 SDS) in 68.7 and 41.6% of patients respectively predicting severe GHD in 85.7% of panhypopituitary patients (subgroup A).
Conclusions: In late adolescent and early adulthood patients, a GH cut-off limit using the GHRH+ARG test lower than 19.0 µg/l is able to discriminate patients with a suspicion of GHD and does not vary from infancy to early adulthood.
This article has been cited by other articles:
![]() |
V Gasco, G Corneli, G Beccuti, F Prodam, S Rovere, J Bellone, S Grottoli, G Aimaretti, and E Ghigo Retesting the childhood-onset GH-deficient patient Eur. J. Endocrinol., December 1, 2008; 159(suppl_1): S45 - S52. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |